Aminoglycosides, ethacrynic acid May increase auditory toxicity. Avoid coadministration.
Antihypertensive agents Antihypertensive effects may be potentiated. Reduce dose by at least 50% when furosemide is coadministered.
Charcoal May reduce absorption of furosemide.
Cisplatin May cause additive ototoxicity.
Digitalis glycosides Electrolyte disturbances may predispose to digitalis-induced arrhythmias.
Lithium May increase plasma lithium levels and toxicity. Avoid coadministration.
Norepinephrine Arterial responsiveness to norepinephrine may be decreased.
NSAIDs May decrease effects of furosemide.
Phenytoin May reduce diuretic effects of furosemide.
Salicylates Because of competition for renal excretion, patients may experience salicylate toxicity. Salicylates may impair diuretic response in patients with cirrhosis and ascites.
Succinylcholine The effects may be potentiated by furosemide.
Sucralfate Natriuretic and antihypertensive effects of furosemide may be decreased; separate the administration times by at least 2 h.
Thiazide diuretics Synergistic effects that may result in profound diuresis and serious electrolyte abnormalities.
Tubocurarine The skeletal muscle relaxant effect may be antagonized by furosemide.
Incompatibility Acid solutions including other parenteral medications (eg, labetalol, ciprofloxacin, amrinone, milrinone): do not add to furosemide solution; precipitate forms.
|